Update on the management of atrial fibrillation: anticoagulation and medical therapy
| Autor: | Hugh Calkins, Shueh Hao Lim, Sunil Sinha |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Pyrrolidines Pyridines Management of atrial fibrillation Amiodarone Anisoles Dabigatran Food and drug administration Vernakalant chemistry.chemical_compound Atrial Fibrillation medicine Humans Intensive care medicine Infusions Intravenous Dronedarone Drug Approval Randomized Controlled Trials as Topic Evidence-Based Medicine business.industry United States Food and Drug Administration Anticoagulants United States Clinical Practice chemistry Practice Guidelines as Topic Benzimidazoles Female Cardiology and Cardiovascular Medicine business Medical therapy Anti-Arrhythmia Agents medicine.drug Factor Xa Inhibitors |
| Zdroj: | Current cardiology reports. 13(5) |
| ISSN: | 1534-3170 |
| Popis: | 2010 saw the introduction of dabigatran (Pradaxa; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT), following US Food and Drug Administration approval, into daily clinical practice in the United States as an alternative to Coumadin (Bristol-Myers-Squibb, New York, NY) therapy. Dronedarone (Multaq; Sanofi-Aventis, Bridgewater, NJ), originally approved for use in the United States in 2009, has seen further widespread deployment in contemporary clinical practice. Intravenous vernakalant (Cardiome Pharm, Vancouver, B.C., Canada; Merck & Co., Whitehouse Station, NJ) is being considered for approval in the United States and may serve as an alternative to current agents for safe and efficacious acute conversion from atrial fibrillation. We focus primarily on new information concerning these and other antiarrhythmic drug and anticoagulation therapies. We provide brief updates of recently published articles along with our perspective on how they will likely alter clinical practice now and in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink